BioSpace News Archive

ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has launched the initial public offering of 7,355,000 shares of its common shares.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, announced unaudited financial results for the quarter ended March 31, 2020.

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, reported its financial results for the first quarter ended March 31, 2020.

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, reported its financial results for the quarter ended March 31, 2020.

BridgeBio Pharma, Inc., reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations.

Arena Pharmaceuticals, Inc. announced that members of its senior management team will participate in two upcoming investor conferences.

Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that research published in the journal Science Translational Medicine describes how a murine version of the investigational agent sotatercept

Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced positive interim Phase 1b data from a study with VIB7734, its novel anti-ILT7 therapy, in patients with cutaneous lupus erythematosus (CLE).

Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today reported financial results and provided program highlights for the first quarter ended March 31, 2020.